

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information only and is not intended to and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



INNOCARE

诺诚健华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9969)

VOLUNTARY ANNOUNCEMENT

INNOCARE WAS RECOGNIZED AS A SPECIALIZED AND NEW “LITTLE GIANT” ENTERPRISE AT THE NATIONAL LEVEL

InnoCare Pharma Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) wishes to inform the shareholders and potential investors of the Company of the attached press release in respect of the Company being recently recognized as a specialized and new “Little Giant” enterprise at the national level by the Ministry of Industry and Information Technology.

According to the Public Notice on the List of the Fifth Batch of Specialized and New “Little Giant” Enterprises and the List of the Second Batch of Specialized and New “Little Giant” Enterprises Passed the Review in Beijing issued by the Beijing Municipal Bureau of Economy and Information Technology recently, Beijing InnoCare Pharma Tech Co., Ltd., a subsidiary of the Company, was selected as the fifth batch of specialized and new “Little Giant” enterprises at national level.

This is a voluntary announcement made by the Company. The Company considers this a milestone to its business commercialization and is thankful to its shareholders’ support.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui

Chairperson and Executive Director

Hong Kong, 21 July 2023

As at the date of this announcement, the Board of Directors comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi, Mr. Ronggang Xie and Mr. Ming Jin as non-executive Directors, and Ms. Lan Hu and Dr. Kaixian Chen as independent non-executive Directors.



INNOCARE

诺诚健华

INNOCARE WAS RECOGNIZED AS A SPECIALIZED AND NEW “LITTLE GIANT” ENTERPRISE AT THE NATIONAL LEVEL

Beijing, China, July 2023– The Ministry of Industry and Information Technology has carried out the cultivation of the fifth batch of specialized and new “Little Giant” enterprises, and has completed the relevant assessment, and recently announced the list of enterprises that have passed the assessment. InnoCare was recognized as a specialized and new “ Little Giant “ enterprise at national level by virtue of its independent innovation and market competitiveness in the field of biopharmaceuticals.

Specialized and new “Little Giant” Enterprises are the best among specialized and new enterprises. They are the leading enterprises focusing on market segments and boasting strong innovation capabilities, large market share, possession of key core technologies, and excellent quality and efficiency. In addition, these enterprises have strong brand influence, and attach importance to the implementation of long-term development strategies, while their core teams have outstanding professional backgrounds and remarkable production and management capabilities, with the potential to develop into international leading enterprises in their fields.

Dr. Jisong Cui, Co-founder, Chairperson and Chief Executive Officer of InnoCare, said, “We are pleased to see that our strength in independent innovation has been recognized by the government and all sectors of society. We will adhere to the development concept of ‘Science-driven Innovation’, enhance our innovation capability and lean management with continuous efforts and follow the ‘specialized and new’ path, thereby contributing to the high-quality development of the biopharmaceutical industry.”

Since its establishment in 2015, InnoCare has been insisting on independent R&D and innovation, and has been awarded numerous qualifications such as National High-Tech Enterprise and Beijing Intellectual Property Demonstration Unit. InnoCare has set up a team of talents with extensive experience in R&D, clinical development, production and commercialization, built an integrated biomedical platform, and created a rich product pipeline with market competitiveness, of which Orelabrutinib has been approved for marketing in China and Singapore and included in China’s national reimbursement drug list (NRDL). Also, the therapy of tafasitamab has been approved for marketing in Hong Kong and has been approved for use in Bo’ao, with 13 innovative drugs at the clinical stage.

About InnoCare

InnoCare (SSE code: 688428; HKEX code: 09969) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. The Company currently has a number of new drug products in the commercial, clinical and pre-clinical R&D stages. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong and the United States.